Table 2. Comparison of Outcome Measures Between the Study Groups Before and After Intervention.

Variable	Timolol gela	Placebo gela	Difference (95% CI)
ESS
Before	4.50 (2.93 to 7.46)	5.65 (2.43 to 8.88)	0.80 (−0.6 to 2.2)
After	2.03 (0.55 to 6.56)	3.04 (1.01 to 7.07)	0.90 (−0.4 to 2.2)
Total NOSE HHT score
Before	1.21 (0.69 to 2.21)	1.24 (0.55 to 2.55)	0.03 (−0.45 to 0.45)
After	0.60 (0.07 to 1.93)	0.64 (0.31 to 1.55)	0.05 (−0.48 to 0.55)
Hemoglobin level, g/dL
Before	13.3 (9.5 to 15.4)	11.8 (8.4 to 16.8)	−1 (−3.1 to 1.4)
After	13.3 (8.3 to 15.9)	12.6 (7.0 to 16.1)	−1.2 (−3.7 to 1.7)
SF-36 domains
PF
Before	78 (35 to 100)	80 (5 to 100)	0 (−30 to 15)
After	90 (35 to 100)	85 (15 to 100)	0 (−40 to 10)
RFP
Before	80 (5 to 100)	75 (0 to 100)	0 (−25 to 50)
After	100 (0 to 100)	100 (0 to 100)	0 (−25 to 50)
RFE
Before	100 (0 to 100)	100 (0 to 100)	0 (0 to 33)
After	100 (0 to 100)	100 (0 to 100)	0 (0 to 0)
EF
Before	48 (10 to 80)	50 (0 to 80)	0 (−15 to 25)
After	70 (30 to 90)	60 (30 to 80)	−5 (−25 to 15)
EW
Before	82 (48 to 96)	84 (36 to 100)	4 (−8 to 12)
After	86 (60 to 100)	86 (76 to 92)	0 (−8 to 12)
SF
Before	100 (25 to 100)	88 (25 to 100)	0 (−33 to 13)
After	100 (50 to 100)	88 (38 to 100)	−13 (−25 to 0)
P
Before	78 (23 to 100)	78 (23 to 100)	0 (−33 to 10)
After	85 (68 to 100)	85 (23 to 100)	0 (−23 to 13)
GH
Before	73 (30 to 100)	60 (10 to 100)	−10 (−30 to 10)
After	80 (35 to 100)	60 (30 to 90)	−20 (−35 to 0)

Abbreviations: EF, energy/fatigue; ESS, Epistaxis Severity Score; EW, emotional well-being; GH, general health; HHT, hereditary hemorrhagic telangiectasia; NOSE HHT, Nasal Outcome Score for Epistaxis in HHT; P, pain; PF, physical functioning; RFE, role limitations due to emotional health; RFP, role limitations due to physical health; SF, social functioning; SF-36, 36-Item Short Form Health Survey.

^aValues expressed as median (range) scores.